

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

II. AMENDMENTS TO THE CLAIMS

1. (Currently amended): (Three Times Amended) A compound of the formula (I):



(I)

wherein

R_1 is selected from the group consisting of C_1 or C_{3-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene;

R_2 and R_3 are independently selected from the group consisting of hydrogen, C_{4-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene

R_4 is selected from the group consisting of a bond and C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene, said alkyl, alkenyl and alkenylene optionally substituted with 1-3 halogen or oxo groups;

R_5 is selected from the group consisting of hydrogen, a 5 or 6 membered aromatic or heteroaromatic group, and a C_{3-12} cycloalkyl;


R_6 is selected from the group consisting of C_{1-10} alkyl and, C_{3-12} cycloalkyl and halogen;

and

n is an integer from 0-3; and a pharmaceutically acceptable salt thereof.

2. (Cancelled)

3. **(Original):** A compound of claim 1 wherein R_2 is butyl.
4. **(Original):** A compound of claim 1 wherein R_4 is selected from a bond, methyl, or ethyl, wherein the methyl and ethyl are optionally substituted with an oxo group.
5. **(Original):** A compound of claim 1, wherein R_5 is phenyl.
6. **(Original):** A compound of claim 1 selected from 1-benzylamino-3-dibutylamino-propyl; 1-[1-benzyl-1-(2-phenyl-1-oxo-ethyl)-amino]-2-dibutylamino-propyl; and pharmaceutically acceptable salts thereof.
7. **(Previously Amended):** A pharmaceutical composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.
8. - 10. **(Withdrawn)**
11. **(Currently amended):** A compound of the formula (I):



(I)

wherein

R_1 is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene;

R_2 **is and R_3 are independently** selected from the group consisting of **hydrogen**, C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene;

R_3 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene;

R_4 is selected from the group consisting of a bond, C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene, said alkyl, alkenyl and alkenylene optionally substituted with 1-3 halogen groups;

R_5 is selected from the group consisting of hydrogen, a 5 or 6 membered aromatic or heteroaromatic group, and a C_{3-12} cycloalkyl;

R_6 is selected from the group consisting of C_{1-10} alkyl, C_{3-12} cycloalkyl and halogen; and n is an integer from 0-3; and a pharmaceutically acceptable salt thereof.

12. **(Previously Amended):** A compound of claim 11 wherein R_1 is propyl.

13. **(Cancelled)**


14. **(Previously Amended):** A compound of claim 11 wherein R_4 is selected from a bond, methyl or ethyl, wherein the methyl and ethyl are optionally substituted with a halogen group.

15. **(Cancelled)**

16. **(Previously Amended):** A pharmaceutical composition comprising a compound of claim 11 and at least one pharmaceutically acceptable excipient.

17. - 22. (Cancelled):

23. (Currently Amended): A compound of the formula (I):



(I)

wherein

R_1 is selected from the group consisting of C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene;

R_2 is selected from the group consisting of hydrogen, C_{5-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene

R_3 is selected from the group consisting of ~~hydrogen~~, C_{1-10} alkyl, C_{2-10} alkenyl and C_{2-10} alkenylene

R_4 is selected from the group consisting of a bond and C_{1-10} alkyl, C_{2-10} alkenyl and a C_{2-10} alkenylene, said alkyl, alkenyl and alkenylene optionally substituted with 1-3 halogen or oxo groups;

R_5 is selected from the group consisting of hydrogen, a 5 or 6 membered aromatic or heteroaromatic group, and a C_{3-12} cycloalkyl;

R_6 is selected from the group consisting of C_{1-10} alkyl, C_{3-12} cycloalkyl and halogen; and n is an integer from 0-3; and a pharmaceutically acceptable salt thereof.

24. **(Previously Added):** A pharmaceutical composition comprising a compound of claim 23 and at least one pharmaceutically acceptable excipient.